Extracorporeal membrane oxygenation (ECMO) is considered a salvage therapy in patients with acute respiratory distress syndrome (ARDS) and refractory hypoxemia (hypoxemia persisting despite lung-protective ventilation). One aspect of ECMO is whether there would be an application of the technology related to the Coronavirus pandemic. The number of people diagnosed with Coronavirus disease (COVID19) has crossed the five million mark on 9 August 2020, with a case fatality rate of 5.2%. Due to this exponential increase in the number of coronavirus disease (COVID19) cases particularly the ones associated with ARDS, experts are evaluating the need for ECMO in intensive care units. Herein, we chronicle a review encompassing the available evidence on ECMO and its potential role in COVID19 ARDS, as we aim for optimal patient care with appropriate resource utilization and conservation.
JayaweeraMPareraHGunawardanaB, et al. Transmission of COVID-19 virus by droplets and aerosols: a critical review on the unresolved dichotomy. Environ Res2020; 188: 109819.
2.
CascellaMRajnikMCuomoA, et al. Features, evaluation and treatment coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, https://www.ncbi.nlm.nih.gov/books/NBK554776/ (2020, accessed 18 May 2020).
3.
PhuaJWengLLingL, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med2020; 8(5): 506–517.
4.
PadenMLConradSARycusPT, et al. Extracorporeal life support organization registry report 2012. ASAIO J2013; 59(3): 202–210.
5.
HillJDO’BrienTGMurrayJJ, et al. Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). Use of the Bramson membrane lung. N Engl J Med1972; 286(12): 629–634.
6.
RozencwajgSGuihotAFranchineauG, et al. Ultra-protective ventilation reduces biotrauma in patients with venovenous extracorporal membrane oxygenation for severe acute respiratory distress syndrome. Crit Care Med2019; 47(11): 1505–1512.
GuanWJLiangWHZhaoY, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J2020; 55(5): 2000547.
10.
WellsCRFitzpatrickMCSahP, et al. Projecting the demand for ventilators at the peak of the COVID-19 outbreak in the USA. Lancet Infect Dis 2020; 20: 1123–1125. DOI: 10.1016/S1473-3099(20)30315-7.
11.
RichardsonSHirschJSNarasimhanM, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA2020; 323(20): 2052–2059.
BloomfieldRNobleDWSudlowA.Prone position for acute respiratory failure in adults. Cochrane Database Syst Rev2015; 2015(11): CD008095.
15.
HoATNPatoliaSGuervillyC. Neuromuscular blockade in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. J Intensive Care2020; 8(1): 12.
16.
GriffithsMJDMcAuleyDFPerkinsGD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res2019; 6(1): e000420.
17.
PeekGJMugfordMTiruvoipatiR, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet2009; 374(9698): 1351–1363.
18.
KollaSAwasSSRichPB, et al. Extracorporeal life support for 100 adult patients with severe respiratory failure. Ann Surg1997; 226(4): 544–564.
19.
AlshahraniMSSindiAAlshamsiF, et al. Extracoropreal membrane oxygenation for severe Middle East respiratory syndrome coronavirus. Ann Intensive Care2018; 8(1): 3.
20.
CombesAHajageDCapellierG, et al., Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome, N Engl J Med2018; 378(21): 1965–1975.
21.
RamanathanKAntogniniDCombesA, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med2020; 8(5): 518–526.
22.
SchmidtMBaileyMSheldrakeJ, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The respiratory extracorporeal membrane oxygenation survival prediction (RESP) score. Am J Respir Crit Care Med2014; 189(11): 1374–1382.
23.
WangDHuBHuC, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA; 323(11): 1061–1069.
24.
HenryBM.COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med2020; 8(4): e24.
25.
HenryBMLippiG.Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): pooled analysis of early reports. J Crit Care2020; 58: 27–28.
26.
LiXGouZLiB, et al. Extracorporeal membrane oxygenation for coronavirus disease 2019 in Shanghai, China. ASAIO J2020; 66(5): 475–481.
27.
HartmanMEHernandezRAPatelK, et al. COVID-19 respiatory failure: targeting inflammation on VV-ECMO support. ASAIO J2020; 66(6): 603–606.
28.
JacobsJPStammersAHSt LouisJ, et al. Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in COVID-19: experience with 32 patients. ASAIO J2020; 66(7): 722–730.
29.
SultanIHabertheuerAUsmanAA, et al. The role of extracorporeal life support for patients with COVID-19: preliminary results from a statewide experience. J Card Surg2020; 35(7): 1410–1413.
30.
ClinicalTrials.gov. Place of ECMO in the management of severe refractory ARDS associated with Covid-19 (ECMO-COVID-19), https://clinicaltrials.gov/ct2/show/NCT04343404 (Identification No. NCT04343404). (accepted 29 June 2020).
31.
ClinicalTrials.gov. Early versus late ECMO therapy in COVID-19 induced ARDS (ECMO-VID) (ECMO-VID), https://clinicaltrials.gov/ct2/show/NCT04341285 (Identification No. NCT04341285). (accepted 23 June 2020).
